WO2017183956A1 - Acide linoléique et acide alpha-linolénique destinés à être utilisés pour réduire le déclin cognitif induit par un stress de vie précoce - Google Patents

Acide linoléique et acide alpha-linolénique destinés à être utilisés pour réduire le déclin cognitif induit par un stress de vie précoce Download PDF

Info

Publication number
WO2017183956A1
WO2017183956A1 PCT/NL2016/050271 NL2016050271W WO2017183956A1 WO 2017183956 A1 WO2017183956 A1 WO 2017183956A1 NL 2016050271 W NL2016050271 W NL 2016050271W WO 2017183956 A1 WO2017183956 A1 WO 2017183956A1
Authority
WO
WIPO (PCT)
Prior art keywords
ala
nutritional composition
lipid
use according
life stress
Prior art date
Application number
PCT/NL2016/050271
Other languages
English (en)
Inventor
Annemarie Oosting
Eline Marleen Van Der Beek
Lidewij SCHIPPERS
Aniko KOROSI
Paulus Johannes LUCASSEN
Original Assignee
N.V. Nutricia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N.V. Nutricia filed Critical N.V. Nutricia
Priority to PCT/NL2016/050271 priority Critical patent/WO2017183956A1/fr
Priority to RU2018140486A priority patent/RU2741495C2/ru
Priority to BR112018071493-3A priority patent/BR112018071493A2/pt
Priority to PCT/NL2017/050246 priority patent/WO2017183970A1/fr
Priority to CN201780037737.2A priority patent/CN109310662A/zh
Priority to EP17719941.1A priority patent/EP3445353A1/fr
Publication of WO2017183956A1 publication Critical patent/WO2017183956A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention is in the field of nutritional compositions, which have a beneficial 5 effect on reducing early-life stress induced cognitive decline, in particular early-life stress experienced by a human subject.
  • the present invention thus concerns a method for preventing early life stress induced decline in cognitive functioning in a human subject, comprising administering to the subject a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12.
  • the method for preventing early life stress induced decline in cognitive functioning is a non-medical method.
  • the invention concerns a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ ALA weight ratio in the range of 0.1 - 12 for use in preventing early life stress induced decline in cognitive functioning in a human subject.
  • the invention can also be worded as the use of linoleic acid (LA) and alpha-linolenic acid (ALA) in the manufacture of a nutritional composition comprising LA and ALA in a LA/ ALA weight ratio in the range of 0.1 - 12 for preventing early life stress induced decline in cognitive functioning in a human subject.
  • the invention can also be worded as the use of a nutritional composition comprising linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ALA weight ratio in the range of 0.1 - 12 for preventing early life stress induced decline in cognitive functioning in a human subject. All said below for the method according to the invention equally applies to the use according to the invention and to the composition for use according to the invention, and vice versa.
  • the nutritional composition that is to be administered according to the method of the invention comprises linoleic acid (LA) and alpha-linolenic acid (ALA) in a LA/ALA weight ratio in the range of 0.1 - 12.
  • LA linoleic acid
  • ALA alpha-linolenic acid
  • the nutritional composition according to the invention may take any form of nutrition suitable to be administered to human subjects, preferably suitable to be administered to human subjects during early life.
  • the nutritional composition according to the invention may be a nutritional supplement, e.g. as an additive to a normal diet, a fortifier, to add to a normal diet, a complete nutrition or an infant nutrition suitable for feeding infants (e.g. infant formula or follow-on formula).
  • the nutritional composition is suitable for feeding infants and/or toddlers.
  • the nutritional composition is selected from an infant formula, a follow-on formula, a growing up milk and a nutritional supplement for pregnant women, most preferably the nutritional composition is an infant formula.
  • the nutritional composition may constitute a complete nutrition or a supplement.
  • the nutritional composition is a complete nutrition.
  • the composition contains a lipid component, a digestible carbohydrate component and a protein component. It may further contain ingredients such as dietary fibres, minerals, vitamins, organic acids, nucleotides and flavouring agents.
  • the lipid component preferably provides 2.9 to 6 g lipid per 100 kcal
  • the protein component preferably provides 1.8 to 5.5 g per 100 kcal, suitably 1.8 to 2.5 g per 100 kcal
  • the digestible carbohydrate component preferably provides 9 to 14 g per 100 kcal, of the composition.
  • the amount of total calories is determined by the sum of calories derived from protein, lipids, digestible carbohydrates and non-digestible oligosaccharides.
  • the nutritional composition of the invention is typically an enteral composition, i.e. intended for oral administration. It is suitably administered in liquid form.
  • the composition may comprise water in which the further components are dissolved or suspended.
  • the composition is thus suitably a liquid, or a solid, typically a powder or tablet, which is reconstitutable with a liquid, suitably with water or other food grade aqueous liquids, to obtain a liquid composition, or in a liquid concentrate form that is to be diluted with water.
  • the liquid composition has a viscosity below 100 mPa.s, more suitably below 60 mPa.s, more suitably below 35 mPa.s, even more suitably below 6 mPa.s as measured in a Brookfield viscometer at 20°C at a shear rate of 100 s "1 .
  • the composition preferably comprises 45 to 200 kcal/100 ml liquid, more preferably 60 to 90 kcal/100 ml liquid, even more preferably 60 to 75 kcal/100 ml liquid. This caloric density ensures an optimal ratio between water and calorie consumption.
  • the osmolarity of the present composition is preferably between 150 and 420 mOsmol/1, more preferably 260 to 360 mOsmol/1.
  • the nutritional composition comprises a lipid component, suitably a lipid component suitable for infant nutrition as known in the art.
  • the lipid component of the present composition suitably provides 2.9 to 6.0 g, preferably 4 to 6 g per 100 kcal of the composition.
  • the nutritional composition preferably comprises 2.1 to 6.5 g lipid per 100 ml, more preferably 3.0 to 4.0 g per 100 ml.
  • the lipid provides preferably 30 to 60 % of the total calories of the composition. More preferably the present composition comprises lipid providing 35 to 55 % of the total calories, even more preferably the present composition comprises lipid providing 40 to 50 % of the total calories.
  • liquid form e.g.
  • the composition preferably comprises 2.1 to 6.5 g lipid per 100 ml, more preferably 3.0 to 4.0 g per 100 ml.
  • the nutritional composition comprises at least 15 wt.% lipid based on dry weight of the composition. Based on dry weight the nutritional composition preferably comprises 10 to 50 wt.%, more preferably 12.5 to 40 wt.% lipid, even more preferably 15 to 35 wt.%) lipid, even more preferably 19 to 30 wt.% lipid.
  • the lipid component comprised in the nutritional composition comprises linoleic acid (LA) and alpha-linolenic acid (ALA).
  • LA linoleic acid
  • alpha-linolenic acid or "ALA” refers to oc- linolenic acid and/or acyl chain (18:3 n3).
  • LA preferably is present in a sufficient amount in order to promote a healthy growth and development.
  • the composition therefore preferably comprises less than 20 wt.% LA based on total fatty acids, preferably from 5 to 15 wt.%).
  • the composition comprises over 5 wt.% LA based on fatty acids, preferably at least 10 wt.% based on total fatty acids.
  • the nutritional composition therefore preferably comprises at least 0.5 wt.% ALA based on total fatty acids preferably comprises at least 1.0 wt.% ALA based on total fatty acids.
  • the composition comprises at least 1.4 wt.% ALA based on total fatty acids, more preferably at least 1.5 wt.%.
  • the nutritional composition comprises less than 10 wt.%) ALA, more preferably less than 5.0 wt.% based on total fatty acids.
  • the nutritional composition comprises at least 10 wt.% LA and at least 1 wt.% ALA, preferably from 10 to 20 wt.% LA and from 1 to 5 wt.% ALA.
  • LA/ALA weight ratio of the nutritional composition according to the present invention is the range of 0.1 - 12, preferably in the range of 0.5 - 11, more preferably in the range of 0.8 - 10, more preferably in the range of 1 - 9, more preferbly in the range of 1 - 8.
  • the lipid components such as LA and ALA, as well as the optionally present further components such as (LC-)PUFAs, may be provided as free fatty acids, in triglyceride form, in diglyceride form, in monoglyceride form, in phospholipid form, or as a mixture of one of more of the above.
  • the nutritional composition comprises triglycerides.
  • the composition comprises at least 70 wt.%, more preferably at least 80 wt.%, more preferably at least 85 wt.% triglycerides, even more preferably at least 90 wt.% triglycerides based on total lipids.
  • the lipids may further comprise one or more of free fatty acids, monoglycerides and diglycerides.
  • the nutritional composition comprises triglycerides derived from vegetable fat.
  • the nutritional composition preferably additionally, comprises phospholipids.
  • the nutritional composition comprises phospholipids derived from non-human mammalian milk.
  • the presence of vegetable lipids advantageously enables an optimal fatty acid profile, high in polyunsaturated fatty acids and more reminiscent to human milk fat.
  • Using lipids from ruminant milk in particular cow's milk alone, or other domestic ruminant mammals, does not provide an optimal fatty acid profile. This less optimal fatty acid profile, such as a large amount of saturated fatty acids, is known to be not beneficial.
  • the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil (flaxseed oil), rape seed oil (such as colza oil, low erucic acid rape seed oil and canola oil), salvia oil, perilla oil, purslane oil, lingonberry oil, sea buckthorn oil, hemp oil, sunflower oil, high oleic sunflower oil, safflower oil, high oleic safflower oil, olive oil, black currant seed oil, echium oil, coconut oil, palm oil and palm kernel oil.
  • linseed oil flaxseed oil
  • rape seed oil such as colza oil, low erucic acid rape seed oil and canola oil
  • salvia oil such as colza oil, low erucic acid rape seed oil and canola oil
  • perilla oil purslane oil
  • lingonberry oil sea buckthorn oil
  • hemp oil sunflower oil
  • the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil, canola oil, coconut oil, sunflower oil and high oleic sunflower oil.
  • the composition comprises 30 to 99.5 wt.% vegetable lipids based on total lipids, more preferably 35 to 99 wt.%, even more preferably of 40 to 95 wt.%, based on total lipids.
  • the nutritional composition comprises fat or lipids from mammalian milk, more preferably from ruminants milk, even more preferably cow's milk, goat milk, sheep milk, buffalo milk, yak milk, reindeer milk, and camel milk, most preferably cow's milk.
  • the mammalian milk is not human milk.
  • the nutritional composition comprises non-human mammalian milk fat.
  • the mammalian milk fat component comprises at least 70 wt.% triglycerides, more preferably at least 90 wt.%, more preferably at least 97 wt.%.
  • the mammalian milk fat is derived from the group consisting of butter, butter fat, butter oil, and anhydrous milk fat, more preferably anhydrous milk fat and butter oil.
  • milk fat lipid sources are high in triglyceride levels.
  • these lipid sources are in the form of a continuous fat phase or in a water-in-oil emulsion form. Using these sources of milk fat during the manufacture of the nutritional composition according to the invention enables the formation of lipid globules, wherein each globule comprises a mixture of vegetable fat and milk fat.
  • the nutritional composition comprises 5 to 70 wt.% non-human mammalian milk lipids based on total lipids.
  • the composition comprises 10 to 65 wt.%), even more preferably 15 to 60 wt.%, even more preferably 25 to 55 wt.% non- human mammalian milk lipids based on total lipids.
  • these milk lipids are selected from the group consisting of butter, butter fat, butter oil, and anhydrous milk fat.
  • the ratio of vegetable fat to milk fat ranges from 3/7 to 20/1.
  • the composition also may comprise non-vegetable lipids and non-milk fat, such as animal fat other than milk fat, such as fish oil, and egg lipid, and microbial, algal, fungal or single cell oils.
  • non-vegetable, non-milk fat is present in an amount of at most 10 wt.% based on total lipid, more preferably at most 5 wt.%.
  • the lipid in the nutritional composition according to the invention comprises a fat source comprising long chain poly-unsaturated fatty acids (LC-PUFA), selected from the group consisting of fish oil, marine oil, algal oil, microbial oil, single cell oil and egg lipid in an amount of 0.25 to 10 wt.% based on total lipid, preferably in an amount of 0.5 to 10 wt.%.
  • LC-PUFA long chain poly-unsaturated fatty acids
  • the lipid is the form of lipid globules.
  • the lipid globules When in liquid form, the lipid globules are emulsified in the aqueous phase.
  • the lipid globules are present in a powder and the powder is suitable for reconstitution with water or another food grade aqueous phase.
  • the lipid globules comprise a core and a surface.
  • the core preferably comprises vegetable fat and milk fat and preferably comprises at least 80 wt.%, more preferably at least 90 wt.% triglycerides and more preferably essentially consists of triglycerides.
  • triglyceride lipids that are present in the composition need necessarily be comprised in the core of lipid globules, but preferably a major part is, preferably more than 50% wt.%, more preferably more than 70 wt.%, even more preferably more than 85 wt.%, even more preferably more than 95 wt.%), most preferably more than 98 wt.%> of the triglyceride lipids that are present in the composition are comprised in the core of lipid globules.
  • the lipid globules have a mode diameter based on volume of above 1.0 ⁇ , preferably above 2.0 ⁇ , preferably above 2.5 ⁇ , more preferably above 3.0 ⁇ .
  • the lipid globules preferably have a mode diameter based on volume of below 6.0 ⁇ , preferably below 5.5 ⁇ , more preferably of below 5.0 ⁇ .
  • the lipid globules have a mode diameter based on volume from 2 to 6 ⁇ , preferably form 2.0 to 6.0 ⁇ , more preferably from 2.5 to 6.0 ⁇ , more preferably from 3.0 to 6.0 ⁇ , even more preferably from 3.0 to 5.5 ⁇ , even more preferably from 3.0 to 5.0 ⁇ .
  • the mode diameter relates to the diameter which is the most present based on volume of total lipid, or the peak value in a graphic representation, having on the X-as the diameter and on the Y-as the volume (%>).
  • a suitable method to determine the volume of lipid globules and their size distribution is by using a Mastersizer particle size analyzer (Malvern Instruments, Malvern, UK), for example by the method described in Michalski et al, 2001, Lait 81 : 787-796.
  • the specific surface area of lipid globules is the surface area per weight of lipid and decreases as the size of globules increases.
  • the specific surface area of the lipid globules can thus be calculated from the particle size distribution of the lipid globules and the concentration and density of the lipid.
  • the lipid globules comprised in the nutritional composition preferably have a specific surface area of 0.5 to 15 m 2 /g lipid, preferably from 1.0 to 10.0 m 2 /g, more preferably from 1.5 to 8.0 m 2 /g, even more preferably from 2.0 to 7.0 m 2 /g lipid.
  • the nutritional composition preferably comprises phospholipids derived from (or "originating from”) non-human mammalian milk. Phospholipids derived from non- human mammalian milk include glycerophospholipids and sphingomyelin.
  • the phospholipids are preferably comprised in a coating on the surface of the lipid globule.
  • 'coating' is meant that the outer surface layer of the lipid globule comprises phospholipids, whereas these phospholipids are virtually absent in the core of the lipid globule.
  • Preferably more than 30 wt.%, preferably more than 50 wt.%, more preferably more than 70 wt,%, even more preferably more than 85 wt.%, most preferably more than 95 wt.% of the phospholipids that are present in the composition are comprised in the coating of lipid globules.
  • the nutritional composition comprises at least 0.5 wt.% phospholipids based on total lipid.
  • phospholipids based on total lipid.
  • at least 80 wt.% of the phospholipids is derived from non-human mammalian milk, more preferably at least 90 wt.%, even more preferably at least 95 wt.%) or 99% wt. or preferably all of the phospholipids is derived from non human mammalian milk.
  • the phospholipids preferably comprise sphingomyelin.
  • Sphingomyelins have a phosphorylcholine or phosphorylethanolamine molecule esterified to the 1 -hydroxy group of a ceramide.
  • the nutritional composition comprises 0.05 to 10 wt.% sphingomyelin based on total lipid, more preferably 0.1 to 5 wt.%, even more preferably 0.2 to 2 wt.%).
  • the nutritional composition comprises at least 15 wt.%, more preferably at least 20 wt.% sphingomyelin based on total phospholipids.
  • the amount of sphingomyelin is below 50 wt.% based on total phospholipids.
  • the phospholipids preferably comprise glycerophospholipids.
  • Glycerophospholipids are a class of lipids formed from fatty acids esterified at the hydroxyl groups on carbon- 1 and carbon-2 of the backbone glycerol moiety and a negatively-charged phosphate group attached to carbon-3 of the glycerol via an ester bond, and optionally a choline group (in case of phosphatidylcholine, PC), a serine group (in case of phosphatidyl serine, PS), an ethanolamine group (in case of phosphatidylethanolamine, PE), an inositol group (in case of phosphatidylinositol, PI) or a glycerol group (in case of phosphatidylglycerol, PG) attached to the phosphate group.
  • a choline group in case of phosphatidylcholine, PC
  • a serine group in case of phosphati
  • the nutritional composition contains PC, PS, PI and/or PE, more preferably at least PS.
  • the nutritional composition comprises at least 1 wt.%, preferably at least 2 wt.% phosphatidyl serine based on total phospholipids.
  • the amount of phosphatidylserine is below 10 wt.% based on total phospholipids.
  • Phospholipids derived from non-human mammalian milk include phospholipids isolated from milk lipid, cream lipid, cream serum lipid, butter serum lipid beta serum lipid, whey lipid, cheese lipid and/or buttermilk lipid.
  • the phospholipids are obtained from milk cream.
  • the phospholipids are preferably derived from milk of cows, mares, sheep, goats, buffalos, horses and camels, most preferably from cow's milk. It is most preferred to use a lipid extract isolated from cow's milk.
  • a suitable source of phospholipids derived from non human mammalian milk is the fraction that can be isolated from milk called milk fat globule membrane (MFGM).
  • the phospholipids that are comprised in the nutritional composition according to the invention are provided as MFGM.
  • the phospholipids are conveniently located on the surface of lipid globules, i.e. comprised in a coating or outer layer.
  • the lipid globules comprise a monolayer comprising phospholipids derived from milk fat.
  • a suitable way to determine whether the polar lipids are located on the surface of the lipid globules is laser scanning microscopy or trans-electron microscopy.
  • the concomitant use of polar lipids in particular phospholipids, derived from domestic animals milk and triglycerides derived from vegetable lipids therefore enables to manufacture coated lipid globules with a coating more similar to human milk, while at the same time providing an optimal fatty acid profile.
  • Methods for obtaining lipid globules with such diameters and/or phospholipid-coatings are disclosed in WO 2010/ 0027258 and WO 2010/0027259.
  • the nutritional composition comprises at least 0.3 wt.% butyric acid and/or acyl chain (BA), based on weight of total fatty acids.
  • the nutritional composition comprises from 0.3 to 4.0 wt.%, preferably 0.3 to 3 wt.%, BA based on weight of total fatty acids.
  • BA based on weight of total fatty acids.
  • the presence of relatively high amounts of BA is characteristic for triglycerides derived from ruminant milk, such as cow's milk. It is not present in vegetable fat or MCT rich fat such as coconut oil and it is also not found in polar lipids derived from milk fat. So one alternative way of describing the presence of milk fat triglycerides in a composition is to define the fatty acid profile in having a BA content from 0.3 to 4.0 wt.% based total fatty acids.
  • the composition preferably comprises at least 0.3 wt.% BA, preferably at least 0.5 wt.%, more preferably at least 0.6 wt.%, more preferably at least 0.8 wt.%.
  • the composition has a wt.% of BA below 4 wt.% based on weight of total fatty acids more preferable below 3 wt.%, more preferable below 2.5 wt.%.
  • the nutritional composition comprises at least 5 wt.% medium chain fatty acids and/or acyl chains (MCFAs) based on total fatty acids, more preferably at least 7 wt.%).
  • MCFA refer to fatty acids and/or acyl chains with a chain length of 8 to 12 carbon atoms.
  • the composition advantageously comprises less than 15 wt.% MCFA based on total fatty acids, more preferably less than 10 wt.%.
  • the nutritional composition comprises 10 to 25 wt.% polyunsaturated fatty acids and/or acyl chains (PUFAs) based on total fatty acids. Amounts above 25 wt.% are higher than present in human milk, and cause technological problems such as stability in the nutritional composition.
  • PUFAs polyunsaturated fatty acids and/or acyl chains
  • the nutritional composition comprises long chain polyunsaturated fatty acids and/or acyl chains (LC-PUFAs), more preferably n-3 LC-PUFA.
  • PUFAs comprise at least 20 carbon atoms in the fatty acyl chain and have 2 or more unsaturated bonds.
  • the present composition comprises eicosapentaenoic acid and/or acyl chain (20:5 n3, EPA), docosapentaenoic acid and/or acyl chain (22:5 n3, DP A) and/or docosahexaenoic acid and/or acyl chain (22:6, n3, DHA), even more preferably DHA.
  • the content of n- 3 LC-PUFA in the nutritional composition preferably does not exceed 5 wt.% of the total fatty acid content.
  • the nutritional composition comprises at least 0.15 wt.%, preferably at least 0.35 wt.%, more preferably at least 0.75 wt.%), n-3 LC-PUFA, more preferably DHA, of the total fatty acid content.
  • the nutritional composition preferably comprises at least 0.25 wt%> LC-PUFA based on total fatty acids.
  • the lipid in the nutritional composition comprises a fat source comprising 0.25 wt.
  • LC-PUFA based on total fatty acids of which at least 0.15 wt%> n-3 LC-PUFA based on total fatty acids selected from the group consisting of DHA, EPA, and DP A, more preferably DHA.
  • the nutritional composition preferably comprises relatively low amounts of ARA.
  • the n-6 LC-PUFA content more preferably ARA content, preferably does not exceed 5 wt.%, more preferably does not exceed 2.0 wt.%, more preferably does not exceed 0.75 wt.%, even more preferably does not exceed 0.5 wt.%), based on total fatty acids.
  • the amount of n-6 LC-PUFA, preferably of ARA is preferably at least 0.02 wt.% more preferably at least 0.05 wt.%, more preferably at least 0.1 wt.% based on total fatty acids, more preferably at least 0.2 wt.%).
  • the presence of preferably low amounts of ARA is especially beneficial in nutrition to be administered to infants below the age of 6 months, since for these infants the infant formulae is generally the only source of nutrition.
  • the n-6 LC- PUFA/n-3 LC-PUFA weight ratio, more preferably ARA/DHA weigh ratio is below 3, more preferably 2 or below, even more preferably 1 or below.
  • the nutritional composition preferably comprises a protein component.
  • the protein component preferably provides 5 to 15% of the total calories.
  • the composition comprises protein that provides 6 to 12% of the total calories. More preferably protein is present in the composition below 9% based on calories.
  • Human milk comprises a lower amount of protein based on total calories than cow's milk.
  • the protein concentration in a nutritional composition is determined by the sum of protein, peptides and free amino acids.
  • the composition preferably comprises less than 12 wt.% protein, more preferably from 9.6 to 12 wt.%, even more preferably from 10 to 11 wt.%.
  • the composition preferably comprises less than 1.5 g protein per 100 ml, more preferably from 1.2 to 1.5 g, even more preferably from 1.25 to 1.35 g.
  • the source of the protein component should be selected in such a way that the minimum requirements for essential amino acid content are met and satisfactory growth is ensured.
  • protein sources based on cows' milk proteins such as whey, casein and mixtures thereof and proteins based on soy, potato or pea are preferred.
  • the nutritional composition according to the invention comprises casein and whey protein.
  • the protein source is preferably based on acid whey or sweet whey, whey protein isolate or mixtures thereof and may include a-lactalbumin and ⁇ - lactoglobulin. More preferably, the protein source is based on acid whey or sweet whey from which caseino-glyco-macropeptide (CGMP) has been removed.
  • CGMP caseino-glyco-macropeptide
  • the composition comprises casein, preferably it comprises at least 3 wt.% casein based on dry weight.
  • casein is intact and/or non-hydrolyzed.
  • protein includes peptides and free amino acids.
  • the nutritional composition comprises a digestible carbohydrate component.
  • the digestible carbohydrate component preferably provides 30 to 80% of the total calories of the composition.
  • the digestible carbohydrate component provides 40 to 60%) of the total calories.
  • the composition preferably comprises 3.0 to 30 g digestible carbohydrate per 100 ml, more preferably 6.0 to 20, even more preferably 7.0 to 10.0 g per 100 ml. Based on dry weight the present composition preferably comprises 20 to 80 wt.%, more preferably 40 to 65 wt.%) digestible carbohydrate.
  • Preferred digestible carbohydrate sources are lactose, glucose, sucrose, fructose, galactose, maltose, starch and maltodextrin.
  • Lactose is the main digestible carbohydrate present in human milk. Lactose advantageously has a low glycemic index.
  • the present composition preferably comprises lactose.
  • the present composition preferably comprises a digestible carbohydrate component, wherein at least 35 wt.%, more preferably at least 50 wt.%, more preferably at least 75 wt.%, even more preferably at least 90 wt.%, most preferably at least 95 wt.% of the digestible carbohydrate is lactose. Based on dry weight the present composition preferably comprises at least 25 wt.% lactose, preferably at least 40 wt.%.
  • the nutritional composition preferably comprises non-digestible oligosaccharides.
  • the present composition comprises non-digestible oligosaccharides with a degree of polymerization (DP) from 2 to 250, more preferably from 3 to 60.
  • Preferred non-digestible oligosaccharides are selected from fructo- oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably galacto-oligosaccharides, most preferably transgalacto- oligosaccharides.
  • the composition comprises a mixture of transgalacto-oligosaccharides and fructo-oligosaccharides.
  • Suitable non-digestible oligosaccharides are for example Vivinal GOS (Frieslandcampina DOMO), Raftilin HP or Raftilose (Orafti).
  • the composition comprises of 80 mg to 2 g non-digestible oligosaccharides per 100 ml, more preferably 150 mg to 1.50 g, even more preferably 300 mg to 1 g per 100 ml. Based on dry weight, the composition preferably comprises 0.25 wt.% to 20 wt.%), more preferably 0.5 wt.% to 10 wt.%, even more preferably 1.5 wt.% to 7.5 wt.%.
  • composition preferably comprises other ingredients, such as vitamins, minerals according to international directives for infant nutrition, in particular infant formulae.
  • the method according to the invention thus concerns administration of the nutritional composition according to the invention during the early life of the human subject.
  • the preferred volume administered on a daily basis is in the range of about 80 to 2500 ml, more preferably about 450 to 1000 ml per day.
  • "preventing” may also be referred to as "reducing", “reducing the risk or occurrence of, "prophylaxis of or “(prophylactic) treatment of.
  • the present use of "preventing early life stress induced decline in cognitive functioning” may also be worded as "stimulating cognitive functioning after exposure to early life stress” or "improving cognitive functioning after exposure to early life stress”.
  • early life typically lasts up to and including adolescence, e.g. up to the age of 18 years, preferably up to the age of 12 years, more preferably up to the age of 5 years, even more preferably up to the age of 36 months, most preferably up to the age of 12 months.
  • Early life also includes the prenatal stage of the human subject, preferably the foetal stage, more preferably the foetal stage in the third trimester of pregnancy. In one embodiment, early life starts at birth.
  • the human subject is preferably selected from the group of unborn foetuses, infants, toddlers, children, preadolescents and adolescents.
  • the human subject is selected form unborn foetuses, infants and toddlers, more preferably from infants and toddlers, i.e. human subjects having an age of 0 - 36 months, most preferably the human subject is an infant, i.e. having an age of 0 - 12 months.
  • the unborn foetus is preferably in the third trimester of pregnancy.
  • Administration to the unborn foetus occurs via the pregnant mother, and the nutritional composition preferably takes the form of a nutritional supplement for pregnant women.
  • the nutritional composition can also be in the form of a nutritional supplement for lactating women.
  • the human subject is at risk or even at high risk of experiencing early life stress, is experiencing early life stress.
  • at (high) risk subjects are subjects, in particular children, from a lower socioeconomic status (e.g. children from families with an income level below average or a low level of education, e.g. not exceeding high school), children whose parents are separated or going through a separation, children separated from one of both parents, children whose parent are both working, neglected children, abused children, children whose parent(s) are suffering from stress, depression, depressed children, ill children, malnurtured children and children exposed to violence.
  • children includes infants and toddlers, preferably the child is an infant.
  • preterm infants and infants small for gestational age (SGA) infants are preterm infants and infants small for gestational age (SGA) infants.
  • a preterm infant relates to an infant born before the standard period of pregnancy is completed, thus before 37 weeks pregnancy of the mother, i.e. before 37 weeks from the beginning of the last menstrual period of the mother.
  • Preterm infants are also referred to as premature infants.
  • SGA infants are those whose birth weight lies below the 10th percentile for that gestational age.
  • Reasons for SGA can be several; for example, term or preterm infants can be born SGA because they have been the subject of intrauterine growth restriction (IUGR). Many preterm infants are also small for gestational age.
  • IUGR intrauterine growth restriction
  • Premature and/or SGA infants include low birth weight infants (LBW infants), very low birth weight infants (VLBW infants), and extremely low birth weight infants (ELBW infants).
  • LBW infants are infants with a birth weight below 2500 g; this group includes term infants born SGA.
  • VLBW and ELBW infants are almost always born preterm and are defined as infants with a birth weight below 1500 g or 1000 g, respectively.
  • the human subject is a preterm infant, an infant born small for gestational age or both.
  • the human subject is a male.
  • administration of the nutritional composition according to the invention typically occurs when the human subject is 18 years old or younger, preferably the human subject has an age below 12 years, more preferably up to 5 years, even more preferably up to 36 months, most preferably up to 12 months.
  • early life typically halts after adolescence, the beneficial effects on cognition may last beyond early life, such as up to or even beyond adulthood. The effects may even last the entire lifespan of the subject.
  • the prevention of early life stress induced cognitive decline prolongs into adulthood.
  • the prevention of declined cognitive functioning is manifest when the subject has reached adulthood or when the subject has reached an age of 18 years or higher, or even an age of 25 years or higher.
  • the nutritional composition according to the invention exhibits a later-in-life effect on cognition.
  • the prevention of early life stress induced decline in cognitive functioning is manifest later-in-life, preferably when the subject has reached an age of 5 years.
  • the beneficial effect on cognition prolongs at least 3 months, preferably at least 1 year, more preferably at least 5 years after administration of the nutritional composition according to the invention has halted.
  • Exemplary of such a later-in-life effect is administration of the composition according to the invention to a foetus, infant or toddler, most preferably to an infant, while the preventive effect on early life stress induced declined cognition is observed at an age of 5 years or older, more preferably at an age of 12 years or older, most preferably at an age of 18 years or older.
  • Early life stress may take any known form. Typical stressors include psychological stressors, physiological stressors and physical stressors.
  • the early life stress may the form of mental stress, physical stress, metabolic stress or any combination thereof.
  • Exemplary stressors include disrupted families (e.g. divorce, separation, blending of families), separation from one or both parents (e.g. incarceration of a parent), maternal depression, both parents working, lack of attention by parent(s), exposure to violence, abuse (e.g. physical, mental, sexual), neglect (e.g. emotional, physical), death of a loved one (in particular death of a parent), illness (e.g. mental, physical), malnutrition.
  • parent(s) may also refer to "care-taker(s)” or “guardian(s)”.
  • the early life stress is selected from malnutrition, maternal stress, depression and abuse.
  • Early life stress induced cognitive decline is a specific type of cognitive decline, which is associated with many complex structures of the brain, such as the cerebral cortex, frontal cortex, hypothalamus, hippocampus and the perirhinal cortex. These structures in the brain play important roles in both cognition and regulating stress responses.
  • the hippocampus for instance contains many stress hormone receptors and is highly plastic. Since these structures develop rapidly in the last trimester of pregnancy and postnatally until the age of about 16 years or beyond, they are particularly sensitive towards early life stress.
  • the declined cognitive functioning preferably includes declined hippocampal-dependent cognitive functioning, or the declined cognitive functioning preferably is declined hippocampal-dependent cognitive functioning.
  • Particularly preferred embodiments of cognitive functioning in the context of the present invention are (a) novel object recognition; (b) the preference for novelty; (c) attention for (change in) surroundings; (d) non-spatial (object) memory; (e) spatial memory and (f) spatial reference memory, but also include novel object recognition and/or novel object location, or hippocampal-dependent memory (especially long term spatial memory).
  • mice with litters were exposed to early life stress paradigm consisting of limited nest/ bedding material as described by Naninck et al., 2015. The stress paradigm was initiated at 2 days after birth of litter (PN2), and lasted until PN9. Litters were weaned at PN21.
  • the experimental diets were semisynthetic diets with a macronutrient and micronutrient composition according to American Institute of Nutrition formulation of ATN93-G purified diets for laboratory rodent (Reeves 1993), and differed only in fatty acid composition with respect to linoleic (LA) and alphalinolenic (ALA) content, see table 1.
  • LA linoleic
  • ALA alphalinolenic
  • mice were subjected to a novel object recognition test (ORT) at day 120.
  • ORT object recognition test
  • This test is a behavioural procedure to study preference for non-spatial object memory based on the innate preference of mice for novelty.
  • mice had to discriminate between a novel object and an object that they had explored previously (familiar).
  • mice were habituated for five minutes/day to the testing arena that consisted of a rectangular plastic box.
  • mice had five minutes to explore two identical objects (9,5 cm high glass bottles) that were placed in the box 12 cm from each other and 11 cm from the wall.
  • OLT Object location tests
  • mice had five minutes to explore the objects and their location.
  • 24h post-training one object was moved to a novel position in the arena and mice were reintroduced into the arena for five min to explore.
  • Time spent exploring was recorded as before and the ratio of novel/familiar object exploration time was calculated. The results are shown in table 2.
  • the ratio novel/old exploration time during ORT is reduced by previous exposure to early life stress in the animals that were fed Diet A indicating that the animals were not able to distinguish between the object they have already seen and the new one that they are seeing for the first time.
  • This index is not reduced by the stress paradigm in animals that were fed Diet B.
  • the difference between the two stressed diet group is statistically significant and indicate that Diet B can prevent stress induced impairments in cognitive performance, in particular novelty preference and non spatial memory performance.
  • mice were also subjected to a Morris Water Maze test at PN 140 also known as Morris Water Maze navigation task, is a behavioral procedure to study cognitive function, in particular spatial learning and memory.
  • animals were trained to locate a hidden platform based on environmental cues.
  • a platform was submerged just below water surface at a fixed position in a round water tank. The tank was in a room with fixed cues on the walls that were visible from the water surface in the tank.
  • mice were trained twice daily (inter trial interval 10 minutes) to locate the hidden platform.
  • animals were placed in the water of the tank and had to locate the platform within 60 seconds. Between trials the starting position of the animal was varied between one of the three quadrants without the platform.
  • the platform was removed from the pool for a single probe trial, in which the time spent in the target quadrant was recorded. This trial is referred to as probe trial.
  • the results are shown in table 3.
  • Table 3 time (%) spent in the target quadrant in the probe trial of the Morris Water Maze.
  • the percentage of time spent in the target quadrant is reduced by previous exposure to early life stress in the animals that were fed Diet A indicating that the animals did not remember as well where the platform was located. Exposure to Diet B, however, prevented the stress- induced impairment in time spent in the target quadrant. This is indicative for an improved cognitive performance, in particular long term (spatial) memory performance.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des compositions nutritionnelles comprenant de l'acide linoléique (LA) et de l'acide alpha-linolénique (ALA) selon un rapport pondéral LA/ALA compris dans la plage allant de 0,1 à 12 et ayant un effet bénéfique sur la prévention du déclin induit par un stress de vie précoce dans le fonctionnement cognitif d'un sujet humain.
PCT/NL2016/050271 2016-04-18 2016-04-18 Acide linoléique et acide alpha-linolénique destinés à être utilisés pour réduire le déclin cognitif induit par un stress de vie précoce WO2017183956A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/NL2016/050271 WO2017183956A1 (fr) 2016-04-18 2016-04-18 Acide linoléique et acide alpha-linolénique destinés à être utilisés pour réduire le déclin cognitif induit par un stress de vie précoce
RU2018140486A RU2741495C2 (ru) 2016-04-18 2017-04-18 Линолевая кислота или альфа-линоленовая кислота для применения с целью уменьшения когнитивных нарушений/снижения нейрогенеза, индуцированных стрессом в раннем периоде жизни
BR112018071493-3A BR112018071493A2 (pt) 2016-04-18 2017-04-18 usos de ácido linoleico (la) e ácido alfa-linolênico (ala) na fabricação de uma composição nutricional, composição nutricional, método para prevenir declínio no funcionamento cognitivo induzido e método para prevenir redução na neurogênese induzida por estresse precoce
PCT/NL2017/050246 WO2017183970A1 (fr) 2016-04-18 2017-04-18 Acide linoléique et acide alpha-linolénique pour utilisation pour réduire les déclin cognitif/réduction de la neurogenèse induit par le stress de vie précoce
CN201780037737.2A CN109310662A (zh) 2016-04-18 2017-04-18 用于减少生命早期应激诱导的认知下降/神经发生减少的亚油酸和α-亚麻酸
EP17719941.1A EP3445353A1 (fr) 2016-04-18 2017-04-18 Acide linoléique et acide alpha-linolénique pour utilisation pour réduire les déclin cognitif/réduction de la neurogenèse induit par le stress de vie précoce

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2016/050271 WO2017183956A1 (fr) 2016-04-18 2016-04-18 Acide linoléique et acide alpha-linolénique destinés à être utilisés pour réduire le déclin cognitif induit par un stress de vie précoce

Publications (1)

Publication Number Publication Date
WO2017183956A1 true WO2017183956A1 (fr) 2017-10-26

Family

ID=56203878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2016/050271 WO2017183956A1 (fr) 2016-04-18 2016-04-18 Acide linoléique et acide alpha-linolénique destinés à être utilisés pour réduire le déclin cognitif induit par un stress de vie précoce

Country Status (1)

Country Link
WO (1) WO2017183956A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073192A2 (fr) * 2005-12-23 2007-06-28 N.V. Nutricia Compositions nutritionnelles destinees a prevenir l'obesite
WO2009002145A1 (fr) * 2007-06-26 2008-12-31 N.V. Nutricia Composition lipidique destinée à améliorer l'activité cérébrale
WO2010027258A1 (fr) 2008-09-02 2010-03-11 N.V. Nutricia Compositions nutritionnelles avec globules lipidiques avec un noyau comprenant des lipides végétaux et un revêtement comprenant des phospholipides ou des lipides polaires
WO2011115476A1 (fr) * 2010-03-17 2011-09-22 N.V. Nutricia Nutrition du nourrisson destinée à améliorer la composition en acides gras des membranes cérébrales à un stade ultérieur de sa vie

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007073192A2 (fr) * 2005-12-23 2007-06-28 N.V. Nutricia Compositions nutritionnelles destinees a prevenir l'obesite
WO2009002145A1 (fr) * 2007-06-26 2008-12-31 N.V. Nutricia Composition lipidique destinée à améliorer l'activité cérébrale
WO2010027258A1 (fr) 2008-09-02 2010-03-11 N.V. Nutricia Compositions nutritionnelles avec globules lipidiques avec un noyau comprenant des lipides végétaux et un revêtement comprenant des phospholipides ou des lipides polaires
WO2010027259A1 (fr) 2008-09-02 2010-03-11 N.V. Nutricia Compositions nutritionnelles à globules lipidiques enrobés
WO2011115476A1 (fr) * 2010-03-17 2011-09-22 N.V. Nutricia Nutrition du nourrisson destinée à améliorer la composition en acides gras des membranes cérébrales à un stade ultérieur de sa vie

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BERNARD JONATHAN Y ET AL: "The association between linoleic acid levels in colostrum and child cognition at 2 and 3 y in the EDEN cohort (vol 77, pg 829, 2015)", PEDIATRIC RESEARCH, vol. 78, no. 3, September 2015 (2015-09-01), pages 356, XP055326920 *
GAO HUI ET AL: "Long-Term Dietary Alpha-Linolenic Acid Supplement Alleviates Cognitive Impairment Correlate with Activating Hippocampal CREB Signaling in Natural Aging Rats", MOLECULAR NEUROBIOLOGY, HUMANA PRESS, US, vol. 53, no. 7, 2 September 2015 (2015-09-02), pages 4772 - 4786, XP036017888, ISSN: 0893-7648, [retrieved on 20150902], DOI: 10.1007/S12035-015-9393-X *
LUCASSEN ET AL., TRENDS IN NEUROSCIENCES, vol. 36, 2013, pages 621 - 631
MICHALSKI ET AL., LAIT, vol. 81, 2001, pages 787 - 796
NANICK ET AL.: "Chronic early life stress alters developmental and adult neurogenesis and impairs cognitive function in mice", HIPPOCAMPUS, vol. 25, no. 3, 2015, pages 309 - 328

Similar Documents

Publication Publication Date Title
AU2013277900B2 (en) Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat
RU2586930C2 (ru) Эффекты метаболического импринтинга специально разработанного липидного компонента
RU2552940C2 (ru) Модулирование постпрандиального поглощения жиров
Bobiński et al. Fatty acids of human milk–a review
WO2010068105A1 (fr) Compositions nutritionnelles à globules lipidiques de grande dimension
WO2013036102A1 (fr) Utilisation d'une préparation pour nourrissons comportant du cholestérol
US20180310605A1 (en) Infant formula with milk fat for promoting healthy growth
EP3599896A1 (fr) Préparation destinée aux nourrissons pour un comportement alimentaire amélioré
US20140248391A1 (en) Use of infant formula with large lipid globules
US20170273343A1 (en) Lipid composition for improving behaviour
US20220386672A1 (en) Infant formula with special lipid architecture for improving postnatal growth of infants born to overweight and obese mothers
AU2022204529B2 (en) Nutritional composition for improving cell membranes
RU2741495C2 (ru) Линолевая кислота или альфа-линоленовая кислота для применения с целью уменьшения когнитивных нарушений/снижения нейрогенеза, индуцированных стрессом в раннем периоде жизни
WO2017183956A1 (fr) Acide linoléique et acide alpha-linolénique destinés à être utilisés pour réduire le déclin cognitif induit par un stress de vie précoce
US20200022396A1 (en) Infant formula for improved eating behaviour
NZ795279A (en) Nutritional composition for improving cell membranes
US20240180860A1 (en) Nutritional composition for improving cell membranes
BR122022003610B1 (pt) Usos de lipídeo na forma de glóbulos lipídicos
NZ621230B2 (en) Use of infant formula with large lipid globules

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16731999

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 16731999

Country of ref document: EP

Kind code of ref document: A1